Genocea Biosciences Company Profile (NASDAQ:GNCA)

Analyst Ratings

Consensus Ratings for Genocea Biosciences (NASDAQ:GNCA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.80 (413.58% upside)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Needham & Company LLCReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Stifel NicolausBoost Price TargetBuy$11.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2015Cowen and CompanyReiterated RatingBuy$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Genocea Biosciences (NASDAQ:GNCA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.42)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2016Q415($0.40)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.43)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.51)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.57)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/12/2015Q414($0.55)($0.66)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.51)($0.53)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.52)($0.76)$0.26 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.44)($0.44)($0.44)
Q4 20161($0.45)($0.45)($0.45)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Genocea Biosciences (NASDAQ:GNCA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Genocea Biosciences (NASDAQ:GNCA)
DateHeadline
07/24/16 08:42 AMIs $40 Price Target Attainable For Genocea Biosciences, Inc. (NASDAQ:GNCA)? - Investor Newswire
07/22/16 04:10 PMNew Broker Ratings For Genocea Biosciences Inc (GNCA) - FTSE News
07/22/16 07:10 AMGenocea Biosciences, Inc. (NASDAQ:GNCA): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 07:50 AMGenocea Biosciences Incorporated (NASDAQ:GNCA) Shorted Shares Decreased By 10.56% - Consumer Eagle
07/20/16 07:09 AMEquity Roundup: Stock Performance Focus on Genocea Biosciences, Inc. (NASDAQ:GNCA) - Press Telegraph
07/19/16 04:23 PMHow Many Genocea Biosciences Inc (NASDAQ:GNCA)'s Analysts Are Bullish? - Consumer Eagle
07/18/16 04:30 PMStrong Sell Calls For Genocea Biosciences, Inc. (NASDAQ:GNCA) At 0 - Investor Newswire
07/16/16 04:04 PMShares Experiencing a Downtrend: Genocea Biosciences, Inc. (NASDAQ:GNCA) - TGP
07/15/16 07:14 AMAnalyst Target and Average Rating Watch: Genocea Biosciences, Inc. (NASDAQ:GNCA) - Press Telegraph
07/15/16 07:14 AMGenocea Biosciences Incorporated (NASDAQ:GNCA) Short Interest Decreased By 4.84% - Consumer Eagle
07/13/16 07:08 AMGenocea Biosciences, Inc. (NASDAQ:GNCA) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 04:19 PMStock Volatility Focus for: Genocea Biosciences, Inc. (NASDAQ:GNCA) - Engelwood Daily
07/11/16 04:19 PMGenocea Biosciences Inc (GNCA) Broker Price Targets For The Coming Week - Fiscal Standard
07/10/16 08:42 AMIs $40 Within Reach For Genocea Biosciences, Inc. (NASDAQ:GNCA)? - Investor Newswire
07/08/16 04:14 PMHC Stocks Momentum: Baxter International Inc (NYSE:BAX), Genocea Biosciences Inc (NASDAQ:GNCA) - share market updates (press release)
07/08/16 07:04 AMGenocea Biosciences Inc. (GNCA) Jumps 5.53% on July 06 - Equities.com
07/07/16 07:04 AMTracking Unusual Volume on Shares of: Genocea Biosciences, Inc. (NASDAQ:GNCA) - Engelwood Daily
07/07/16 07:04 AMCompany Stock Focus for Genocea Biosciences, Inc. (NASDAQ:GNCA): Which Way Will Shares Head? - Press Telegraph
07/06/16 08:58 AMGenocea Biosciences Incorporated (NASDAQ:GNCA) Shorts Decreased by 4.84% After Short Covering - Press Telegraph
07/06/16 08:58 AMGenocea Biosciences Inc. (GNCA) Jumps 5.37% on July 04 - Equities.com
07/06/16 07:21 AMGenocea to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management ...
07/06/16 07:00 AMGenocea to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - CAMBRIDGE, Mass., July 06, 2016-- Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company ...
07/04/16 03:55 PMShare Performance Recap for: Genocea Biosciences, Inc. (NASDAQ:GNCA) - Press Telegraph
07/03/16 08:44 AMGenocea Biosciences, Inc. (NASDAQ:GNCA) Expected to Reach Highs Of $40 - Investor Newswire
07/03/16 08:44 AMHow Many Genocea Biosciences Inc (NASDAQ:GNCA)'s Analysts Are Bullish? - Press Telegraph
07/02/16 07:12 AMGenocea Biosciences Inc. (GNCA) Drops 7.24% on June 30 - Equities.com
07/01/16 07:03 AMGenocea Biosciences Inc. (GNCA) is Trading Higher on Unusual Volume for June 29 - Equities.com
06/30/16 04:33 PMGenocea Biosciences, Inc. (NASDAQ:GNCA) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 07:05 AMCovering the Bases on Genocea Biosciences, Inc. (NASDAQ:GNCA): Where is the Stock Going? - Press Telegraph
06/29/16 07:04 AMCheck on Share Volatility: Genocea Biosciences, Inc. (NASDAQ:GNCA) - Engelwood Daily
06/29/16 07:04 AMGenocea Biosciences Inc. (GNCA) Jumps 14.25% on June 28 - Equities.com
06/27/16 04:09 PMBroker Outlook For The Week Ahead Genocea Biosciences Inc (GNCA) - Fiscal Standard
06/27/16 08:41 AMStrong Sell Calls Recommendations For Genocea Biosciences, Inc. (NASDAQ:GNCA) At 0 - Investor Newswire
06/27/16 08:41 AMGenocea Biosciences Incorporated (NASDAQ:GNCA) Sellers Covered 4.84% of Their Shorts - Engelwood Daily
06/25/16 08:06 AMHC Stocks Broker Alerts: Baxter International Inc (NYSE:BAX), Genocea Biosciences Inc (NASDAQ:GNCA) - share market updates (press release)
06/25/16 08:06 AMGenocea Biosciences Inc. (GNCA) Jumps 26.56% on June 23 - Equities.com
06/20/16 04:04 PMThis Weeks Broker Views For Genocea Biosciences Inc (GNCA) - Fiscal Standard
06/19/16 08:33 AMStrong Buy Calls Count For Genocea Biosciences, Inc. (NASDAQ:GNCA) At 4 - Investor Newswire
06/17/16 04:08 AMGenocea Biosciences Inc (GNCA) Current Analyst Ratings - Fiscal Standard
06/16/16 08:35 AMGenocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
06/14/16 03:49 PMcooper ronald harold wilfred - [at noodls] - FORM 3 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 1.... This is an abstract of the original noodl. To continue reading this document, click here for the original ...
06/11/16 04:20 AMGenocea Biosciences Inc. (GNCA) Drops 5.38% on June 09 - Equities.com
06/10/16 03:49 PMcooper, ronald harold wilfred - [at noodls] - FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ... This is an abstract of the original noodl. To continue reading this document, ...
06/09/16 04:49 PMcurrent report - [at noodls] - Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. ... This is an abstract of the original noodl. ...
06/09/16 04:24 PMGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/09/16 03:49 PMGenocea Appoints Ron Cooper to Board of Directors - [at noodls] - CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Ron ...
06/08/16 04:32 PMGENOCEA BIOSCIENCES INC. (NASDAQ:GNCA) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:22 PMGENOCEA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/04/16 04:16 PMGenocea Biosciences Inc. (GNCA) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/02/16 04:29 AMGenocea Biosciences Inc (GNCA) is Trading Higher on Unusual Volume for May 31 - Equities.com - Genocea Biosciences Inc (GNCA) is Trading Higher on Unusual Volume for May 31Equities.comGenocea Biosciences Inc (GNCA) experienced unusually high volume on May. 31, as the stock gained 18.09% to a closing price of $4.70. The stock saw 1.55 million shares trade hands over the course of the day on 5,380 trades. Given that the stock's ...Buy, Sell Or Hold Rating For Genocea Biosciences Inc (GNCA)?Share Trading NewsInsiders Are Gradually Buying Genocea Biosciences, Inc. (NASDAQ:GNCA)HNNall 3 news articles »

Social

About Genocea Biosciences

Genocea Biosciences logoGenocea Biosciences, Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment. It has one product candidate in Phase II clinical development: GEN-003, which is a therapeutic vaccine or immunotherapy for the treatment of genital herpes infections. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. The Company's pipeline also includes GEN-005, which is under malaria prophylaxis, Epstein-Barr virus and immuno-oncology programs in research stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GNCA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.06
  • 50 Day Moving Average: $4.21
  • 200 Day Moving Average: $4.28
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $114.30M
  • Beta: 2.1
  • Current Year EPS Consensus Estimate: $-1.74 EPS
  • Next Year EPS Consensus Estimate: $-1.94 EPS
Additional Links:
Genocea Biosciences (NASDAQ:GNCA) Chart for Monday, July, 25, 2016